Citadel Advisors
IPSC icon

Citadel Advisors’s Century Therapeutics IPSC Stock Holding History

Citadel Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275K Buy
+112,300
New +$257K ﹤0.01% 11323
2025
Q1 		– Sell
-1,500
Closed -$1.51K – 15003
2024
Q4 		$1.51K Sell
1,500
-8,700
-85% -$11.8K ﹤0.01% 14179
2024
Q3 		$17.4K Buy
10,200
+9,900
+3,300% +$19.4K ﹤0.01% 12888
2024
Q2 		$765 Hold
300
– – ﹤0.01% 13921
2024
Q1 		$1.25K Sell
300
-100
-25% -$423 ﹤0.01% 14154
2023
Q4 		$1.33K Sell
400
-1,300
-76% -$2.37K ﹤0.01% 13846
2023
Q3 		$3.4K Buy
1,700
+1,600
+1,600% +$4.26K ﹤0.01% 13589
2023
Q2 		$316 Sell
100
-2,000
-95% -$6.45K ﹤0.01% 14152
2023
Q1 		$7.29K Sell
2,100
-200
-9% -$878 ﹤0.01% 13742
2022
Q4 		$11.8K Buy
+2,300
New +$21.7K ﹤0.01% 13553

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors's IPSC Position: Q2 2026 in Review

Citadel Advisors opened a new position in Century Therapeutics (IPSC) in Q2 2026: 126,470 shares worth $310K. The stake represents ﹤0.01% of the portfolio and ranks #11044 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in IPSC as recently as Q4 2025.

Citadel Advisors first reported a position in IPSC in Q3 2021 and has held it in 17 quarters since. The position peaked at $673K in Q4 2022. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Citadel Advisors held 126,470 shares of Century Therapeutics worth $310K as of Q2 2026.
  • Century Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Century Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11044 holding.
  • Citadel Advisors first reported a position in Century Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • Citadel Advisors's Century Therapeutics position peaked at $673K in Q4 2022.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.